Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Pelthos Therapeutics Inc.AMEX: PTHS
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt rises 772.9% from a year ago
Net debt stood at $20.71M at the end of Q1 FY2026, up 772.9% from a year earlier and up 23.2% from the prior quarter. Over 3 fiscal years it compounded at +225.9% a year.
Context
- Net debt amounted to 14.2% of total assets at the end of Q1 FY2026, down 246.1 pp from a year earlier.
- Net debt increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +772.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- 16.81M USD
- Year-over-year change
- +904.7%
- 3-year CAGR
- +225.9%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.81M | +904.7% |
| FY2024 | 2024-12-31 | 1.67M | +42.7% |
| FY2023 | 2023-12-31 | 1.17M | +141.5% |
| FY2022 | 2022-12-31 | 485.36K | — |
Net Debt vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's Mar 2026 net debt of $20.71M is the highest of the 4 companies compared; the peer median is -$2.19M.
- Its year-over-year change of +772.9% is the highest of 4, against a peer median of -58.4%.
- Net debt amounts to 14.2% of total assets for PTHS, versus a peer median of 20.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $20.71M | +772.9% | +225.9% | 14.2% | |
| Dec 2025 | -$1.37M | +50.6% | — | 0.1% | |
| Mar 2026 | -$2.19M | -58.4% | — | 20.2% | |
| Mar 2026 | -$18.46M | -316.1% | — | 59.8% | |
| Peer median (excluding PTHS) | -$2.19M | -58.4% | — | 20.2% | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.